Submission Details
| 510(k) Number | K231038 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | April 12, 2023 |
| Decision Date | July 26, 2023 |
| Days to Decision | 105 days |
| Submission Type | Traditional |
| Review Panel | Cardiovascular (CV) |
| Summary | Summary PDF |
K231038 is an FDA 510(k) clearance for the Global Hypoperfusion Index (GHI) Algorithm, a Medium-term Adjunctive Predictive Cardiovascular Indicator (Class II — Special Controls, product code QNL), submitted by Edwards Lifesciences, LLC (Irvine, US). The FDA issued a Cleared decision on July 26, 2023, 105 days after receiving the submission on April 12, 2023. This device falls under the Cardiovascular review panel. Regulated under 21 CFR 870.2210.
| 510(k) Number | K231038 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | April 12, 2023 |
| Decision Date | July 26, 2023 |
| Days to Decision | 105 days |
| Submission Type | Traditional |
| Review Panel | Cardiovascular (CV) |
| Summary | Summary PDF |
| Product Code | QNL — Medium-term Adjunctive Predictive Cardiovascular Indicator |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 870.2210 |
| Definition | The Adjunctive Predictive Cardiovascular Indicator Is A Prescription Device That Uses Software Algorithms To Analyze Cardiovascular Vital Signs And Predict Future Cardiovascular Status Or Events Within A Defined Medium-term Period. This Device Is Intended For Adjunctive Use With Other Physical Vital Sign Parameters And Patient Information And Is Not Intended To Independently Direct Therapy. |